

Basel, 31 January 2019

## Roche reports very strong results in 2018

- Group sales increase 7%<sup>1</sup> at constant exchange rates and in Swiss francs
- Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Tecentriq, Alecensa and Hemlibra
- Diagnostics Division sales grow 7%, primarily due to demand for immunodiagnostic solutions
- In the fourth quarter, the US FDA approves Tecentriq in combination with Avastin for a specific form of lung cancer; Venclexta for a form of leukaemia; and Xofluza for influenza
- Core earnings per share grow ahead of sales at 19%, or 8% excluding the effect of the US tax reform
- On IFRS basis, net income increases 24%
- Board proposes dividend to increase to CHF 8.70
- Outlook for 2019: Sales are expected to grow in the low- to mid-single digit range, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

Key figures January - December 2018	CHF millions		% change	
	2018	2017	At CER <sup>1</sup>	In CHF
Group sales	56,846	53,299	+7	+7
Pharmaceuticals Division	43,967	41,220	+7	+7
Diagnostics Division	12,879	12,079	+7	+7
Core operating profit	20,505	19,012	+9	+8
Core EPS - diluted (CHF)	18.14	15.34	+19	+18
excl. US tax reform			+8	+7
IFRS net income	10,865	8,825	+24	+23

<sup>1</sup> Unless otherwise stated, all growth rates in this document are at constant exchange rates (CER: average 2017).

Commenting on the Group's results, Roche CEO Severin Schwan said: "In 2018, Roche achieved very good growth in both divisions. I am particularly pleased with the very strong demand for our new medicines, delivering significant benefit for patients fighting serious diseases like cancer, multiple sclerosis and haemophilia. Roche is also making major progress in driving digitalisation, and in leveraging real-world healthcare data and analytics to support product development and advance personalised healthcare. Based on the successful launches and our strong product pipeline Roche is well positioned for continued growth."

## Group results

In 2018, Group sales rose 7% to CHF 56.8 billion. Core operating profit increased 9%, reflecting the strong underlying business performance. Core EPS grew 19% and IFRS net income increased 24%, including the benefits from the US tax reform and higher net financial income.

Sales in the Pharmaceuticals Division increased 7% to CHF 44.0 billion. Key growth drivers were the new multiple sclerosis medicine Ocrevus and cancer medicines Perjeta, Tecentriq, Alecensa as well as the new haemophilia medicine Hemlibra. With sales of CHF 2.4 billion in its first full year on key markets, Ocrevus is the most successful new product launch in the history of Roche. As expected, the strong uptake of newly introduced medicines was partially offset by lower sales of MabThera/Rituxan and of Tarceva.

In the US, sales increased 14%, led by Ocrevus, Perjeta and Lucentis. Ocrevus sales were supported by continued strong new patient demand as well as follow-up treatments. The 32% sales increase of Perjeta was driven by its use for adjuvant (after surgery) treatment of patients with HER2-positive early breast cancer at high risk of recurrence.<sup>2</sup>

In Europe (-7%), sales were affected by competition from biosimilars for MabThera/Rituxan (-47%) and Herceptin (-16%), offset by the strong launches of our new medicines Ocrevus, Tecentriq, Alecensa, and of Perjeta in metastatic HER2-positive breast cancer and adjuvant therapy.

In the International region, sales grew 10%, led by the Asia-Pacific and Latin America subregions. In Japan, sales declined 1% due to government price cuts and biosimilar competition for MabThera/Rituxan (-36%) and Herceptin (-16%).

Diagnostics Division sales increased 7% to CHF 12.9 billion. Centralised and Point of Care Solutions (+8%) was the main contributor, led by the growth of its immunodiagnosics business (+11%). All business areas reported sales increases. In regional terms, growth was driven by Asia-Pacific (+13%) and North America (+7%). Sales increased 3% in EMEA<sup>3</sup>, 9% in Latin America, and 6% in Japan.

---

<sup>2</sup> US Food and Drug Administration prescribing information for Perjeta

<sup>3</sup> EMEA = Europe, Middle East and Africa

## Important milestones for Roche medicines

Roche medicines passed important regulatory milestones in recent months, including the following key achievements: In December 2018, the US Food and Drug Administration (FDA) approved Tecentriq in combination with Avastin, paclitaxel and carboplatin for the initial treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations.

The FDA granted accelerated approval to Venclexta in combination with azacitidine or decitabine, or low dose cytarabine, for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), aged 75 years and older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions.<sup>4</sup> AML is the most common type of aggressive leukaemia in adults and has the lowest survival rate of all types of leukaemia.

In October, FDA approved Xofluza (baloxavir marboxil) for the treatment of acute, uncomplicated influenza in people aged 12 years and older. Xofluza is a first-in-class, single-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme essential for viral replication.<sup>5</sup> It has demonstrated efficacy against a wide range of influenza viruses, including oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.<sup>6</sup>

Based on the IMpower133 study, the FDA granted priority review for Tecentriq, in combination with carboplatin and etoposide (chemotherapy), for the initial treatment of people with extensive-stage small cell lung cancer (ES-SCLC). The IMpower133 results represent the first clinically meaningful advance in the disease in over 20 years.<sup>7</sup>

Priority review was granted for Tecentriq plus Abraxane (albumin-bound paclitaxel; *nab*-paclitaxel) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. The priority review was based on the IMpassion 130 study, the first positive phase III immunotherapy study in TNBC, an aggressive disease with limited treatment options.

Polatuzumab vedotin in combination with MabThera/Rituxan plus bendamustine has been granted breakthrough therapy designation and orphan drug designation by the FDA, as well as PRIME designation and orphan drug designation by the European Medical Agency (EMA), for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma who are not candidates for haematopoietic stem cell transplantation. Files for regulatory review and approval of polatuzumab have been submitted to FDA.

---

<sup>4</sup> Venclexta/Venclyxto sales are booked by partner AbbVie.

<sup>5</sup> Shi F, et al. Viral RNA polymerase: a promising antiviral target for influenza A virus. *Curr Med Chem*. 2013;20(31):3923–34

<sup>6</sup> Taniguchi K, et al. Inhibitory Effect of S-033188, a novel inhibitor of influenza virus cap-dependent endonuclease, against avian influenza A/H7N9 virus in vitro and in vivo. Poster presentation at ESWI, September 2017.

<sup>7</sup> Evans WK, et al. *J Clin Oncol*, 1985

Entrectinib, in development for the treatment of neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours, was granted breakthrough therapy designation by the FDA, PRIME designation by the EMA, and Sakigake and orphan drug designations by the health authorities in Japan. Files for regulatory review and approval of entrectinib have been submitted to FDA.

### **Advancing personalised healthcare**

In 2018, Roche concluded several transactions to further advance its personalised healthcare strategy. This includes three US-based companies: Foundation Medicine, with its comprehensive genomic profiling assays to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies, immunotherapies and clinical trials; Flatiron Health, a market leader in the curation and development of real-world evidence for cancer research; Ignyta, with entrectinib as its lead drug candidate. Entrectinib is an example of highly targeted novel treatment approaches based on genetic profiling.

In early 2018, Roche Diagnostics and GE Healthcare announced their agreement to enter into a strategic partnership, combining Roche's *in vitro* diagnostics Know-how with GE Healthcare's *in vivo* expertise. The aim is to co-develop and co-market decision support software solutions, anchored by a shared digital platform designed to also allow third parties to potentially place their product and company-agnostic applications. The initial focus is on oncology and acute care.

### **Outlook for 2019**

Sales are expected to grow in the low- to mid-single digit range, at constant exchange rates. Core earnings per share are targeted to grow broadly in line with sales, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.

### **Dividend proposal**

The Board of Directors proposes a dividend increase to CHF 8.70 per share and non-voting equity security. Subject to approval by the Annual General Meeting of Shareholders on 5 March 2019, this will be Roche's 32<sup>nd</sup> consecutive annual dividend increase.

## Pharmaceuticals Division

Sales January - December 2018	CHF millions		As % of sales		% change	
	2018	2017	2018	2017	At CER	In CHF
Pharmaceuticals Division	43,967	41,220	100.0	100.0	+7	+7
United States	23,233	20,496	52.8	49.7	+14	+13
Europe	8,693	9,051	19.8	22.0	-7	-4
Japan	3,701	3,713	8.4	9.0	-1	0
International*	8,340	7,960	19.0	19.3	+10	+5

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

### Clinical trial results on Roche medicines

Roche announced results from a number of late-stage studies during the fourth quarter, including the following studies: The phase III Katherine study met its primary endpoint, showing that Kadcyca as a single agent reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by half compared to Herceptin as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual disease present following neoadjuvant (before surgery) treatment.

Data from the primary analysis of the phase III Haven 2 study evaluating Hemlibra prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors showed that nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds. Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-patient comparison. Hemlibra every two weeks and every four weeks also showed clinically meaningful control of bleeding.

Results of the head-to-head phase III study of Alecensa versus crizotinib in an Asian patient population with ALK-positive advanced or metastatic NSCLC showed a reduction in the risk of disease worsening or death by 78%. Alecensa lowered the risk of tumour spread or growth in the brain or central nervous system by 86%.

An integrated analysis of the pivotal entrectinib phase II Startrk-2, phase I Startrk -1 and phase I Alka-372-001 trials showed that entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours. The study data also demonstrate the potential of entrectinib to treat a range of difficult-to-treat and rare cancers regardless of their site of origin.

Based on the positive phase III results, Roche will be moving forward with satralizumab for neuromyelitis optica spectrum disorder (NMOSD). Roche will be solely responsible for the global regulatory filings and commercialisation except in Japan, Taiwan and Korea. The programme transition from Chugai to Roche was initiated in January 2019.

## Key pharmaceutical products

**HER2-franchise** (Herceptin, Perjeta and Kadcyła, +7%). For HER2-positive breast cancer and HER2-positive metastatic gastric cancer (Herceptin only).

**Herceptin** (+1%). For HER2-positive breast cancer and HER2-positive metastatic gastric cancer. Sales increases were mainly driven by growth in the US and in China. This growth was partially offset by the sales decline in Europe (-16%) due to the first biosimilar launches from mid-2018.

**Avastin** (+3%). For advanced colorectal, breast, lung, kidney, cervical and ovarian cancer, and relapsed glioblastoma (a type of brain tumour). Sales increased in the International region (+12%), in particular in China due to broader market penetration, in the US (+1%) and in Japan (+3%), but declined in Europe (-1%).

**MabThera/Rituxan** (-8%). For forms of blood cancer, rheumatoid arthritis and certain types of vasculitis. Sales development was impacted by Europe (-47%) as a result of the market entry of biosimilars. In the US, sales increased 4%, with growth in both the immunology and oncology segments, also driven by the subcutaneous formulation. Sales were also higher in the International region (+11%), particularly in China due to broader market penetration.

**Actemra/RoActemra** (+12%). For rheumatoid arthritis, forms of juvenile idiopathic arthritis and giant cell arteritis as well as CAR T cell-induced severe or life-threatening cytokine release syndrome. Sales growth was reported in all regions, driven by the continued uptake of the subcutaneous formulation.

**Xolair** (+11%, US only). For chronic idiopathic urticaria and allergic asthma. Growth was driven by demand in both indications.

**Lucentis** (+18%, US only). For eye conditions including neovascular ('wet') age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, and diabetic retinopathy. Growth was driven by the ongoing rollout of prefilled syringes and sales increases in all approved indications.

## Highlights on medicines launched since 2012

**Perjeta.** For HER2-positive breast cancer. Sales (CHF 2.8 billion, +27%) grew in all regions. As of December 2018, Perjeta was registered in 73 countries including the US, the EU and recent approvals in Japan and China for adjuvant treatment. This indication strongly supports its continued growth, which is also driven by increased demand in adjuvant early breast cancer therapy in the US and in neoadjuvant metastatic usage in Europe.

**Ocrevus** (CHF 2.4 billion, +172%). For both the relapsing and primary progressive forms of multiple sclerosis (MS). Ocrevus has now been approved in 74 countries, with more than 80,000 people treated globally as of December 2018. Strong demand in both indications has continued.

**Esbriet** (CHF 1.0 billion, +19%). For idiopathic pulmonary fibrosis (IPF). Sales continued to expand, driven by growth in the US (+19%) and Europe (+17%).

**Tecentriq** (CHF 772 million, +59%). For advanced bladder cancer, advanced lung cancer and initial therapy of non-squamous NSCLC. Sales growth was reported by all regions, mainly driven by Europe, notably in Germany, and by the launch in Japan in 2018.

**Alecensa** (CHF 637 million, +76%). For ALK-positive lung cancer. Alecensa showed continued strong sales growth across all regions, with the US and Europe as the main drivers.

**Gazyva/Gazyvaro** (CHF 390 million, +40%). For chronic lymphocytic leukaemia (CLL), rituximab-refractory follicular lymphoma and previously untreated advanced follicular lymphoma. Sales expanded, especially in Europe and in the US.

**Hemlibra** (CHF 224 million). For people with haemophilia A with inhibitors to factor VIII. Hemlibra is approved in more than 50 countries, including the US, the EU and Japan. In several countries, including the US, Hemlibra is also approved for people with haemophilia A without factor VIII inhibitors. Hemlibra is the only prophylactic treatment that can be administered subcutaneously and at multiple dosing options (once weekly, every two weeks or every four weeks).

Top-selling pharmaceuticals	Total		United States		Europe		Japan		International*	
	CHFm	%	CHFm	%	CHFm	%	CHFm	%	CHFm	%
Herceptin	6,982	1	2,908	9	1,849	-16	249	-16	1,976	10
Avastin	6,849	3	2,904	1	1,820	-1	847	3	1,278	12
MabThera/Rituxan	6,752	-8	4,290	4	916	-47	188	-36	1,358	11
Perjeta	2,773	27	1,325	32	915	15	143	18	390	45
Ocrevus	2,353	172	2,080	144	206	**	-	-	67	**
Actemra/RoActemra	2,160	12	857	14	701	7	354	15	248	15
Xolair	1,912	11	1,912	11	-	-	-	-	-	-
Lucentis	1,659	18	1,659	18	-	-	-	-	-	-
Activase/TNKase	1,284	6	1,231	6	-	-	-	-	53	5
Esbriet	1,031	19	754	19	230	17	-	-	47	29

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* over 500%

## Diagnosics Division

Sales	CHF millions		As % of sales		% change	
	2018	2017	2018	2017	At CER	In CHF
January - December 2018						
Diagnosics Division	12,879	12,079	100.0	100.0	+7	+7
Business Areas						
Centralised and Point of Care Solutions	7,768	7,179	60.3	59.4	+8	+8
Molecular Diagnostics	2,019	1,920	15.7	15.9	+5	+5
Diabetes Care	1,980	1,965	15.4	16.3	+2	+1
Tissue Diagnostics	1,112	1,015	8.6	8.4	+10	+10
Regions						
Europe, Middle East, Africa	4,986	4,773	38.7	39.5	+3	+4
Asia-Pacific	3,334	2,939	25.9	24.4	+13	+13
North America	3,213	3,011	24.9	24.9	+7	+7
Latin America	844	884	6.6	7.3	+9	-5
Japan	502	472	3.9	3.9	+6	+6

In October, Roche officially opened a new manufacturing site and R&D centre in Suzhou, China, to support the future diagnostic needs within China and the region. With its regional headquarters in Singapore and eight existing branches across China, Roche is already a major healthcare provider in Asia-Pacific.



**Centralised and Point of Care Solutions** (+8%) was the largest contributor to the division's sales growth. Serum Work Area solutions, comprising the immunodiagnostics (+11%) and clinical chemistry (+7%) businesses, were the main growth drivers.

cobas pro integrated solution, a Serum Work Area solution for medium throughput to lower high throughput laboratories was launched in countries accepting the CE mark. This new generation of SWA solutions provides a high level of efficiency and continuous loading of supplies. Furthermore, it offers simplicity through automated maintenance and calibration. It also features the broadest SWA assay menu consolidated on a single platform, short assay incubation times and low sample volume requirements.

Sales in **Molecular Diagnostics** increased 5%. In virology, sales were up 4%, with strong growth in HIV monitoring. Sales in the blood screening and human papillomavirus (HPV) screening businesses grew 9% and 8% respectively. Continued high demand was reported for cobas Liat tests, the new system for molecular point of care testing.

The Navify Tumor Board, a cloud-based software solution that fundamentally changes the way oncology care teams prepare for, conduct and document clinical treatment decisions, was further extended by the launch of the Navify Clinical Trial Match and Navify Publication Search apps in 2018. These apps scan globally renowned resources and are fully integrated with the Navify Tumor Board and represent the start of the Navify apps ecosystem, with more apps from Roche, partners and third parties to follow.

**Tissue Diagnostics** sales increased 10%. The advanced staining business continued its strong growth (+10%); demand for the primary staining portfolio was high (+13%).

The Ventana DP 200 slide scanner was launched in March 2018, creating high-quality tissue slide images that offer pathologists a digital image that accurately reproduces what would be seen under the microscope. These images serve as the basis for a full menu of image analysis algorithms currently under development. Roche also launched uPath enterprise software, a universal digital pathology software for lab administrators, histotechnicians and pathologists. This software allows for improved case management, including case sharing among colleagues to seek second opinions. More importantly, uPath software enables pathologists with patient-centric case viewing for quick diagnosis, and will provide a platform for a full menu of image analysis algorithms currently under development.

**Diabetes Care** sales increased 2%, mainly driven by the new Accu-Chek Guide and Accu-Chek Instant blood glucose monitoring systems. Launched in pilot markets, the new Accu-Chek Solo micropump received encouraging customer feedback. An enhanced positive acceptance is visible for the integrated diabetes management solutions including mySugr.

#### **Roche's Full Year Results 2018 – Presentation in London and live video webcast**

The Roche Full Year Results 2018 presentation takes place in London today. Further details are available [here](#). A live video webcast will be available on <http://ir.roche.com>.

## About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people's lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world's largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit [www.roche.com](http://www.roche.com).

All trademarks used or mentioned in this release are protected by law.

## Additional information

- Full Year 2018 Presentation: <https://www.roche.com/irp190131-a.pdf>
- Full Year 2018 Presentation with appendix: <https://www.roche.com/irp190131.pdf>
- Annual Report: <https://www.roche.com/investors/annualreport18.htm>
- Dow Jones Sustainability Indices : <http://www.sustainability-indices.com>

Disclaimer: Cautionary statement regarding forward-looking statements

This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, among others: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche's earnings or earnings per share for any current or future period will necessarily match or exceed the historical published earnings or earnings per share of Roche

**Roche Investor Relations**

Dr. Karl Mahler

Phone: +41 61 68-78503

e-mail: [karl.mahler@roche.com](mailto:karl.mahler@roche.com)

Dr. Sabine Borngräber

Phone: +41 61 68-88027

e-mail: [sabine.borngraeber@roche.com](mailto:sabine.borngraeber@roche.com)

Dr. Birgit Masjost

Phone: +41 61 68-84814

e-mail: [birgit.masjost@roche.com](mailto:birgit.masjost@roche.com)

**Investor Relations North America**

Loren Kalm

Phone: +1 650 225 3217

e-mail: [kalm.loren@gene.com](mailto:kalm.loren@gene.com)

Jon Kaspar Bayard

Phone: +41 61 68-83894

e-mail: [jon\\_kaspar.bayard@roche.com](mailto:jon_kaspar.bayard@roche.com)

Dr. Bruno Eschli

Phone: +41 61 68-75284

e-mail: [bruno.eschli@roche.com](mailto:bruno.eschli@roche.com)

Dr. Gerard Tobin

Phone: +41 61 68-72942

e-mail: [gerard.tobin@roche.com](mailto:gerard.tobin@roche.com)

Dr. Lisa Tuomi

Phone: +1 650 467 8737

e-mail: [tuomi.lisa@gene.com](mailto:tuomi.lisa@gene.com)

## Appendix: Tables

1.	Sales January to December 2018 and 2017 .....	13
2.	Quarterly sales and constant exchange rate sales growth by Division in 2018 and 2017 .....	14
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017 .....	15
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017 .....	16
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017 .....	17
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth .....	18
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States .....	19
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	20
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan.....	21
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International .....	22
11.	Roche Group consolidated income statement for the twelve months ended 31 December 2018 .....	23
12.	Roche Group core results reconciliation – Full Year 2018 .....	24
13.	Divisional core results reconciliation – Full Year 2018.....	25
14.	Roche Group consolidated balance sheet.....	26
15.	Roche Group consolidated statement of cash flows .....	27

1. Sales January to December 2018 and 2017

CHF millions	Twelve months ended 31 December		% change	
	2018	2017	At CER	In CHF
Pharmaceuticals Division	43,967	41,220	7	7
United States	23,233	20,496	14	13
Europe	8,693	9,051	-7	-4
Japan	3,701	3,713	-1	0
International*	8,340	7,960	10	5
Diagnostics Division	12,879	12,079	7	7
Roche Group	56,846	53,299	7	7

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2018 and 2017

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Pharmaceuticals Division	10,584	6	10,672	7	11,175	7	10,855	7	11,265	8
United States	5,230	12	5,516	15	5,862	15	5,814	12	6,041	14
Europe	2,285	-5	2,287	-7	2,241	-8	2,079	-7	2,086	-6
Japan	1,038	6	851	0	930	0	919	0	1,001	-5
International*	2,031	3	2,018	5	2,142	6	2,043	14	2,137	14
Diagnostics Division	3,281	4	2,911	5	3,353	7	3,114	6	3,501	10
Roche Group	13,865	5	13,583	6	14,528	7	13,969	7	14,766	9

\*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017

Top-selling pharmaceuticals January - December 2018	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Herceptin	6,982	1	2,908	9	1,849	-16	249	-16	1,976	10
Avastin	6,849	3	2,904	1	1,820	-1	847	3	1,278	12
MabThera/Rituxan	6,752	-8	4,290	4	916	-47	188	-36	1,358	11
Perjeta	2,773	27	1,325	32	915	15	143	18	390	45
Ocrevus	2,353	172	2,080	144	206	**	-	-	67	**
Actemra/RoActemra	2,160	12	857	14	701	7	354	15	248	15
Xolair	1,912	11	1,912	11	-	-	-	-	-	-
Lucentis	1,659	18	1,659	18	-	-	-	-	-	-
Activase/TNKase	1,284	6	1,231	6	-	-	-	-	53	5
Esbriet	1,031	19	754	19	230	17	-	-	47	29

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017

New products January - December 2018	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	258	4	160	0	71	6	-	-	27	31
Perjeta	2,773	27	1,325	32	915	15	143	18	390	45
Kadcyla	979	8	359	5	376	5	75	6	169	22
Gazyva/Gazyvaro	390	40	195	24	136	64	13	-	46	21
Esbriet	1,031	19	754	19	230	17	-	-	47	29
Cotellic	60	1	14	-14	35	-2	-	-	11	43
Alecensa	637	76	284	65	99	261	188	27	66	355
Tecentriq	772	59	469	4	152	**	81	-	70	468
Ocrevus	2,353	172	2,080	144	206	**	-	-	67	**
Hemlibra	224	**	154	**	42	**	26	-	2	-
Xofluza	13	-	13	-	-	-	-	-	-	-

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%



5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2018 vs. YTD December 2017

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Herceptin	6,982	1	2,908	9	1,849	-16	249	-16	1,976	10
Avastin	6,849	3	2,904	1	1,820	-1	847	3	1,278	12
MabThera/Rituxan	6,752	-8	4,290	4	916	-47	188	-36	1,358	11
Perjeta	2,773	27	1,325	32	915	15	143	18	390	45
Ocrevus	2,353	172	2,080	144	206	**	-	-	67	**
Actemra/RoActemra	2,160	12	857	14	701	7	354	15	248	15
Xolair	1,912	11	1,912	11	-	-	-	-	-	-
Lucentis	1,659	18	1,659	18	-	-	-	-	-	-
Activase/TNKase	1,284	6	1,231	6	-	-	-	-	53	5
Esbriet	1,031	19	754	19	230	17	-	-	47	29
Kadcyla	979	8	359	5	376	5	75	6	169	22
Tecentriq	772	59	469	4	152	**	81	-	70	468
Pulmozyme	739	2	506	1	133	4	1	18	99	7
CellCept	669	-4	107	-11	179	-3	80	1	303	-4
Alecensa	637	76	284	65	99	261	188	27	66	355
Tarceva	538	-36	233	-49	113	-21	73	-21	119	-21
Mircera	532	5	-	-	76	-13	205	-4	251	21
Xeloda	427	-6	35	-3	17	-38	111	3	264	-7
Gazyva	390	40	195	24	136	64	13	-	46	21
Tamiflu	378	-29	168	-29	25	-10	95	-37	90	-24

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Herceptin	1,781	6	1,774	2	1,850	2	1,683	1	1,675	-3
Avastin	1,691	1	1,640	-2	1,778	1	1,690	6	1,741	5
MabThera/Rituxan	1,768	-3	1,713	-8	1,741	-11	1,656	-7	1,642	-6
Perjeta	579	22	613	18	700	28	699	27	761	35
Ocrevus	369	-	479	-	561	195	633	104	680	83
Actemra/RoActemra	519	14	499	13	550	13	529	9	582	14
Xolair	428	15	442	7	486	14	498	9	486	12
Lucentis	288	-11	393	6	425	27	413	2	428	47
Activase/TNKase	299	0	323	8	329	10	317	1	315	4
Esbriet	232	17	222	13	250	15	267	21	292	26
Kadcyla	243	12	235	6	249	11	244	8	251	7
Tecentriq	132	65	139	29	181	44	204	71	248	89
Pulmozyme	199	10	169	0	188	6	180	1	202	3
CellCept	182	-1	158	-8	175	-4	175	4	161	-9
Alecensa	118	99	119	81	160	98	158	62	200	69
Tarceva	205	-21	141	-32	157	-31	127	-37	113	-44
Mircera	141	3	120	5	128	4	150	16	134	-4
Xeloda	112	-28	102	-2	114	-11	110	-2	101	-8
Gazyva	76	42	84	27	93	38	104	51	109	44
Tamiflu	138	-52	292	11	28	-75	13	-63	45	-67

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Herceptin	696	16	728	13	766	11	711	11	703	0
Avastin	701	1	699	-3	743	-1	730	5	732	3
MabThera/Rituxan	1,017	6	1,023	4	1,104	3	1,066	5	1,097	7
Perjeta	257	18	287	18	339	36	342	34	357	38
Ocrevus	363	-	443	-	496	163	560	82	581	59
Actemra/RoActemra	199	16	192	15	219	17	212	8	234	17
Xolair	428	15	442	7	486	14	498	9	486	12
Lucentis	288	-11	393	6	425	27	413	2	428	47
Activase/TNKase	285	0	311	8	315	11	303	1	302	4
Esbriet	164	11	155	8	180	12	200	21	219	33
Kadcyla	89	15	86	2	92	12	91	6	90	1
Tecentriq	115	48	107	5	112	-7	110	-4	140	21
Pulmozyme	137	11	106	-10	133	7	125	2	142	4
CellCept	26	-29	25	-19	29	-14	32	16	21	-24
Alecensa	55	112	56	66	77	107	71	56	80	44
Tarceva	110	-24	61	-41	65	-46	57	-52	50	-56
Mircera	-	-	-	-	-	-	-	-	-	-
Xeloda	3	-94	8	38	9	-54	9	50	9	183
Gazyva	40	42	43	19	50	29	52	24	50	25
Tamiflu	42	-70	161	10	3	-100	3	-86	1	-100

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Herceptin	552	6	551	-3	525	-7	419	-21	354	-34
Avastin	457	-3	469	-3	464	-1	437	-1	450	1
MabThera/Rituxan	361	-26	282	-44	243	-50	206	-49	185	-46
Perjeta	200	21	215	13	223	8	233	15	244	25
Ocrevus	3	-	28	-	50	*	52	*	76	*
Actemra/RoActemra	169	12	172	9	175	2	176	11	178	8
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	55	17	56	21	58	19	55	15	61	14
Kadcyla	89	3	92	1	94	1	94	7	96	9
Tecentriq	12	*	23	*	37	*	46	*	46	286
Pulmozyme	33	1	33	-4	34	5	32	8	34	8
CellCept	47	-1	44	-5	46	-4	44	-1	45	0
Alecensa	12	*	17	*	20	349	23	137	39	217
Tarceva	34	-18	30	-23	31	-22	27	-19	25	-21
Mircera	20	-14	19	-17	20	-17	19	-7	18	-8
Xeloda	5	-25	5	-32	4	-33	4	-52	4	-27
Gazyva	25	58	29	64	34	66	36	79	37	52
Tamiflu	12	-81	21	45	1	117	0	-33	3	-77

\* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Herceptin	79	-1	59	-10	64	-19	60	-19	66	-17
Avastin	223	5	184	2	220	4	213	2	230	2
MabThera/Rituxan	81	5	54	-11	51	-33	46	-40	37	-54
Perjeta	34	15	28	11	35	12	34	12	46	35
Ocrevus	-	-	-	-	-	-	-	-	-	-
Actemra/RoActemra	87	15	73	14	91	18	91	16	99	13
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Kadcyla	19	6	16	1	19	12	20	8	20	3
Tecentriq	-	-	-	-	15	-	29	-	37	-
Pulmozyme	-	-	-	-	-	-	-	-	1	-
CellCept	22	14	17	6	21	3	20	0	22	-4
Alecensa	44	39	37	27	49	36	49	26	53	20
Tarceva	24	-11	17	-23	22	-9	18	-19	16	-34
Mircera	59	-1	43	-1	52	-5	52	-4	58	-4
Xeloda	29	5	24	0	30	6	27	5	30	1
Gazyva	-	-	-	-	-	-	5	-	8	-
Tamiflu	60	36	74	14	1	-96	4	-77	16	-73

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International\*

CHF millions	Q4 2017	% change vs. Q4 2016	Q1 2018	% change vs. Q1 2017	Q2 2018	% change vs. Q2 2017	Q3 2018	% change vs. Q3 2017	Q4 2018	% change vs. Q4 2017
Herceptin	454	-5	436	-8	495	4	493	13	552	32
Avastin	310	1	288	2	351	9	310	21	329	15
MabThera/Rituxan	309	0	354	11	343	4	338	18	323	12
Perjeta	88	45	83	34	103	56	90	42	114	46
Ocrevus	3	-	8	-	15	**	21	**	23	459
Actemra/RoActemra	64	16	62	15	65	25	50	-4	71	24
Xolair	-	-	-	-	-	-	-	-	-	-
Lucentis	-	-	-	-	-	-	-	-	-	-
Activase/TNKase	14	5	12	14	14	4	14	-1	13	3
Esbriet	13	263	11	61	12	43	12	40	12	-5
Kadcyla	46	29	41	33	44	35	39	13	45	14
Tecentriq	5	300	9	357	17	434	19	**	25	458
Pulmozyme	29	15	30	69	21	4	23	-11	25	-8
CellCept	87	9	72	-8	79	-1	79	4	73	-11
Alecensa	7	**	9	500	14	403	15	289	28	343
Tarceva	37	-19	33	-24	39	-10	25	-14	22	-37
Mircera	62	16	58	19	56	25	79	44	58	-3
Xeloda	75	11	65	-3	71	-3	70	-3	58	-17
Gazyva	11	15	12	-2	9	10	11	58	14	24
Tamiflu	24	-45	36	2	23	-59	6	-4	25	11

\* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

\*\* Over 500%

## 11. Roche Group consolidated income statement for the twelve months ended 31 December 2018

in millions of CHF	Pharma- ceuticals	Diagnostics	Corporate	Group
<b>Sales</b>	<b>43,967</b>	<b>12,879</b>	-	<b>56,846</b>
Royalties and other operating income	2,553	98	-	2,651
Cost of sales	(10,491)	(6,778)	-	(17,269)
Marketing and distribution	(7,068)	(3,041)	-	(10,109)
Research and development	(10,299)	(1,793)	-	(12,092)
General and administration	(3,874)	(748)	(636)	(5,258)
<b>Operating profit</b>	<b>14,788</b>	<b>617</b>	<b>(636)</b>	<b>14,769</b>
Financing costs				(770)
Other financial income (expense)				149
<b>Profit before taxes</b>				<b>14,148</b>
Income taxes				(3,283)
<b>Net income</b>				<b>10,865</b>
Attributable to				
- Roche shareholders				10,500
- Non-controlling interests				365
<b>Earnings per share and non-voting equity security</b>				
Basic (CHF)				12.29
Diluted (CHF)				12.21

## 12. Roche Group core results reconciliation – Full Year 2018

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Alliances & business combinations	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
<b>Sales</b>	<b>56,846</b>	-	-	-	-	-	-	-	-	<b>56,846</b>
Royalties and other operating income	2,651	(16)	-	-	-	-	-	-	-	2,635
Cost of sales	(17,269)	400	1,111	294	-	-	-	-	-	(15,464)
Marketing and distribution	(10,109)	168	36	-	-	-	-	-	-	(9,905)
Research and development	(12,092)	110	147	788	-	-	-	-	-	(11,047)
General and administration	(5,258)	245	-	2,254	35	159	5	-	-	(2,560)
<b>Operating profit</b>	<b>14,769</b>	<b>907</b>	<b>1,294</b>	<b>3,336</b>	<b>35</b>	<b>159</b>	<b>5</b>	-	-	<b>20,505</b>
Financing costs	(770)	2	-	-	15	9	-	-	-	(744)
Other financial income (expense)	149	-	-	-	-	-	-	-	-	149
<b>Profit before taxes</b>	<b>14,148</b>	<b>909</b>	<b>1,294</b>	<b>3,336</b>	<b>50</b>	<b>168</b>	<b>5</b>	-	-	<b>19,910</b>
Income taxes	(3,283)	(150)	(184)	(229)	(29)	(37)	(1)	(35)	19	(3,929)
<b>Net income</b>	<b>10,865</b>	<b>759</b>	<b>1,110</b>	<b>3,107</b>	<b>21</b>	<b>131</b>	<b>4</b>	<b>(35)</b>	<b>19</b>	<b>15,981</b>
Attributable to										
- Roche shareholders	10,500	759	1,097	3,097	21	131	4	(35)	19	15,593
- Non-controlling interests	365	-	13	10	-	-	-	-	-	388
EPS - diluted (CHF)	12.21	0.88	1.29	3.60	0.02	0.16	-	(0.04)	0.02	18.14



### 13. Divisional core results reconciliation – Full Year 2018

in millions of CHF	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Alliances & business combinations	Legal & environmental	Pension plan settlements	Core
<b>Pharmaceuticals</b>								
Sales	43,967	-	-	-	-	-	-	43,967
Royalties and other operating income	2,553	-	-	-	-	-	-	2,553
Cost of sales	(10,491)	292	969	(274)	-	-	-	(9,504)
Marketing and distribution	(7,068)	97	32	-	-	-	-	(6,939)
Research and development	(10,299)	76	130	507	-	-	-	(9,586)
General and administration	(3,874)	58	-	2,147	91	24	5	(1,549)
<b>Operating profit</b>	<b>14,788</b>	<b>523</b>	<b>1,131</b>	<b>2,380</b>	<b>91</b>	<b>24</b>	<b>5</b>	<b>18,942</b>
<b>Diagnostics</b>								
Sales	12,879	-	-	-	-	-	-	12,879
Royalties and other operating income	98	(16)	-	-	-	-	-	82
Cost of sales	(6,778)	108	142	568	-	-	-	(5,960)
Marketing and distribution	(3,041)	71	4	-	-	-	-	(2,966)
Research and development	(1,793)	34	17	281	-	-	-	(1,461)
General and administration	(748)	38	-	107	(56)	131	-	(528)
<b>Operating profit</b>	<b>617</b>	<b>235</b>	<b>163</b>	<b>956</b>	<b>(56)</b>	<b>131</b>	<b>-</b>	<b>2,046</b>
<b>Corporate</b>								
General and administration	(636)	149	-	-	-	4	-	(483)
<b>Operating profit</b>	<b>(636)</b>	<b>149</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>4</b>	<b>-</b>	<b>(483)</b>

## 14. Roche Group consolidated balance sheet

in millions of CHF	31 December 2018	31 December 2017	31 December 2016
<b>Non-current assets</b>			
Property, plant and equipment	21,818	20,912	19,957
Goodwill	8,948	10,077	11,282
Intangible assets	9,346	8,368	12,046
Deferred tax assets	3,895	3,576	2,826
Defined benefit plan assets	877	801	738
Other non-current assets	1,389	1,370	1,300
<b>Total non-current assets</b>	<b>46,273</b>	<b>45,104</b>	<b>48,149</b>
<b>Current assets</b>			
Inventories	6,621	7,407	7,928
Accounts receivable	9,776	9,577	8,760
Current income tax assets	208	348	335
Other current assets	2,521	2,243	2,540
Marketable securities	6,437	7,278	4,944
Cash and cash equivalents	6,681	4,719	4,163
<b>Total current assets</b>	<b>32,244</b>	<b>31,572</b>	<b>28,670</b>
<b>Total assets</b>	<b>78,517</b>	<b>76,676</b>	<b>76,819</b>
<b>Non-current liabilities</b>			
Long-term debt	(16,077)	(15,839)	(16,992)
Net deferred tax liabilities	(384)	(495)	(838)
Defined benefit plan liabilities	(7,017)	(7,421)	(7,678)
Provisions	(1,452)	(1,548)	(1,777)
Other non-current liabilities	(188)	(206)	(532)
<b>Total non-current liabilities</b>	<b>(25,118)</b>	<b>(25,509)</b>	<b>(27,817)</b>
<b>Current liabilities</b>			
Short-term debt	(2,693)	(3,121)	(5,363)
Current income tax liabilities	(3,808)	(3,408)	(2,713)
Provisions	(2,329)	(2,042)	(2,271)
Accounts payable	(3,526)	(3,454)	(3,375)
Other current liabilities	(10,677)	(10,135)	(8,878)
<b>Total current liabilities</b>	<b>(23,033)</b>	<b>(22,160)</b>	<b>(22,600)</b>
<b>Total liabilities</b>	<b>(48,151)</b>	<b>(47,669)</b>	<b>(50,417)</b>
<b>Total net assets</b>	<b>30,366</b>	<b>29,007</b>	<b>26,402</b>
<b>Equity</b>			
Capital and reserves attributable to Roche shareholders	27,622	26,441	23,911
Equity attributable to non-controlling interests	2,744	2,566	2,491
<b>Total equity</b>	<b>30,366</b>	<b>29,007</b>	<b>26,402</b>

## 15. Roche Group consolidated statement of cash flows

in millions of CHF	FY 2018	FY 2017
<b>Cash flows from operating activities</b>		
Cash generated from operations	24,424	22,256
(Increase) decrease in net working capital	176	427
Payments made for defined benefit plans	(785)	(538)
Utilisation of provisions	(883)	(621)
Disposal of products	335	410
Other operating cash flows	0	(1)
<b>Cash flows from operating activities, before income taxes paid</b>	<b>23,267</b>	<b>21,933</b>
Income taxes paid	(3,288)	(3,909)
<b>Total cash flows from operating activities</b>	<b>19,979</b>	<b>18,024</b>
<b>Cash flows from investing activities</b>		
Purchase of property, plant and equipment	(4,043)	(3,509)
Purchase of intangible assets	(879)	(704)
Disposal of property, plant and equipment	146	100
Disposal of intangible assets	0	0
Business combinations	(3,374)	(280)
Divestment of subsidiaries	1	11
Interest and dividends received	24	30
Sales of equity securities and debt securities	566	762
Purchases of equity securities and debt securities	(412)	(319)
Sales (purchases) of money market instruments and time accounts over three months, net	672	(2,612)
Other investing cash flows	104	62
<b>Total cash flows from investing activities</b>	<b>(7,195)</b>	<b>(6,459)</b>
<b>Cash flows from financing activities</b>		
Proceeds from issue of bonds and notes	2,252	1,502
Redemption and repurchase of bonds and notes	(2,152)	(3,068)
Increase (decrease) in commercial paper	(199)	(1,258)
Increase (decrease) in other debt	(23)	(385)
Hedging and collateral arrangements	12	235
Changes in ownership interests in subsidiaries	(2,287)	0
Changes in non-controlling interests	0	0
Equity contribution by non-controlling interests - capital injection	0	5
Interest paid	(593)	(648)
Dividends paid	(7,253)	(7,140)
Equity-settled equity compensation plans, net of transactions in own equity	(448)	(358)
Other financing cash flows	0	0
<b>Total cash flows from financing activities</b>	<b>(10,691)</b>	<b>(11,115)</b>
Net effect of currency translation on cash and cash equivalents	(131)	106
<b>Increase (decrease) in cash and cash equivalents</b>	<b>1,962</b>	<b>556</b>
Cash and cash equivalents at beginning of period	4,719	4,163
<b>Cash and cash equivalents at end of period</b>	<b>6,681</b>	<b>4,719</b>